The first study of its kind in Brazil on national drug spending illustrates how the threat of compulsory licensing can be an excellent bargaining tool to reducing patented drug costs.
The Wall Street Journal defends patents, but disingenuously confuses the problems of high drug costs and poor delivery. Yet, the two issues are independent and require different approaches.